



Claim 1. (Currently Amended) A compound of formula I






I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure i, ii, iii, or iv



B is



W is NHC(=X)R₁, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is S(=O)(=N-R₅);

R₁ is

- (a) H,
- (b) NH₂,
- (c) NHC₁₋₄alkyl,
- (d) C₁₋₄alkyl,

E1

- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) (CH₂)_pC₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF₃, CH₂, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; when R₅ is C₁₋₄alkyl

substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;


p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3.

E1
Claim 2. (Previously presented) A compound of claim 1 having the formula IA:



IA.

Claim 3. (Original) A compound of claim 2 wherein R₁ is C₁₋₄alkyl.

Claim 4. (Original) A compound of claim 2 wherein R₁ is ethyl.

Claim 5. (Original) A compound of claim 2 wherein R₁ is methyl.

Claim 6. (Original) A compound of claim 2 wherein R₁ is C₃₋₆cycloalkyl.

Claim 7. (Original) A compound of claim 2 wherein R₁ is cyclopropyl.

Claim 8. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 2-7 wherein X is a sulfur atom.

Claim 9. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 2-7 wherein X is an oxygen atom.


Claim 10. (Original) A compound of claim 8 wherein one of R₂ and R₃ is H, the other one is F.

Claim 11. (Original) A compound of claim 9 wherein one of R₂ and R₃ is H, the other one is F.

Claim 12. (Original) A compound of claim 8 wherein R₄ is H.

Claim 13. (Original) A compound of claim 9 wherein R₄ is H.


Claim 14. (Original) A compound of claim 8 wherein structure B is



wherein Z is S(=O)(=NR₅).


Claim 15. (Canceled).

Claim 16. (Currently Amended) A compound of claim 8 wherein structure B is



wherein Z is S(=O)(=NR₅) .

Claim 17. (Original) A compound of claim 9 wherein structure B is



wherein Z is S(=O)(=NR₅).

Claims 18-21. (Canceled).

Claim 22. (Original) A compound of claim 14 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Claim 23. (Original) A compound of claim 22 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 24. (Original) A compound of claim 14 wherein R₅ is C(=O)CH₃.

Claim 25. (Original) A compound of claim 14 wherein R₅ is C(=O)OCH₃.

E/
Claims 26-29. (Canceled).

Claim 30. (Original) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.

Claim 31. (Original) The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

Claim 32. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

Claim 33. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

Claim 34. (Original) A method for treating microbial infections of claim 30 wherein the infection is skin infection.

Claim 35. (Original) A method for treating microbial infections of claim 30 wherein the infection is eye infection.

Claim 36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 37. (Canceled)

Claim 38. (Original) A compound of claim 16 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

E!

Claim 39. (Original) A compound of claim 38 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 40. (Original) A compound of claim 16 wherein R₅ is C(=O)CH₃.

Claim 41. (Original) A compound of claim 16 wherein R₅ is C(=O)OCH₃.

Claim 42. (Original) A compound of claim 17 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Claim 43. (Original) A compound of claim 42 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 44. (Original) A compound of claim 17 wherein R₅ is C(=O)CH₃.

Claim 45. (Original) A compound of claim 17 wherein R₅ is C(=O)OCH₃.

Claim 46. (Previously Presented) A compound of claim 2 which is

N-((5S)-3-[3-fluoro-4-[1-(acetylmino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(acetylmino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;


N-((5S)-3-[3-fluoro-4-(1-[(methylamino)carbonyl]imino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

S/

N-((*(5S*)-3-[3-fluoro-4-(1-[[ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-((*(5S*)-3-[3-fluoro-4-(1-[[4-nitrophenyl)amino]carbonyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-((*(5S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-((*(5S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;
N-[((*(5S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1*λ*⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]propanethioamide;
N-[((*(5S*)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1*λ*⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide ;
N-[((*(5S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl] cyclopropanecarbothioamide, *Z*-isomer;
N-[((*(5S*)-3-{3-fluoro-4-[1-[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, *Z*-isomer; or
N-((*(5S*)-3-[3-fluoro-4-(1-[(benzylamino)carbonyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer.


Claim 47. (Currently amended) 4- A compound of formula II



II


or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



E /

B is





W is NHC(=X)R₁, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is S(=O)(=N-R₅) and the B ring has the following stereochemistry



R₁ is

- (a) H,
- (b) NH₂,
- (c) NHC₁₋₄alkyl,
- (d) C₁₋₄alkyl,
- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or

(h) $(CH_2)_p C_{3-6}$ cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (a) H,
- (b) C₁₋₄alkyl,
- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, CF₃, CH₂, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; when R₅ is C₁₋₄alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

~~and --- in structure iii is either a double bond or a single bond.~~

Claim 48. (Previously presented) The compound of claim 47 wherein R₁ is C₁₋₄alkyl.

Claim 49. (Previously presented) The compound of claim 47 wherein R₁ is ethyl.

E /

Claim 50. (Previously presented) The compound of claim 47 wherein R₁ is methyl.

Claim 51. (Previously presented) The compound of claim 47 wherein R₁ is C₃₋₆cycloalkyl.

Claim 52. (Previously presented) The compound of claim 47 wherein R₁ is cyclopropyl.

Claim 53. (Currently Amended) The compound of claim 47 wherein X is a sulfur atom.

Claim 54. (Currently Amended) The compound of claim 47 wherein X is an oxygen atom.

Claim 55. (Previously Presented) The compound of claim 53 wherein one of R₂ and R₃ is H, the other one is F.

Claim 56. (Previously Presented) The compound of claim 54 wherein one of R₂ and R₃ is H, the other one is F.

Claim 57. (Previously presented) The compound of claim 47 wherein R₅ is H.

Claim 58. (Previously presented) The compound of claim 47 wherein R₅ is C₁₋₄alkyl, optionally substituted with OH; or C₁₋₄alkyl substituted with C(=O)NHC₁₋₄alkyl, C(=O)NH₂ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, NO₂, CF₃, or CN.

Claim 59. (Previously presented) The compound of claim 47 wherein R₅ is CH₃, or ethyl.

Claim 60. (Previously presented) The compound of claim 47 wherein R₅ is C₁₋₄alkyl substituted with phenyl wherein the phenyl is optionally substituted with NO₂.

E 1
Claim 61. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Claim 62. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 63. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)CH₃.

Claim 64. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)OCH₃.

Claim 65. (Previously presented) A compound of claim 47 which is

N-((5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide (Z)-isomer;
N-((5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide (Z)-isomer;
N-((5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide (Z)-isomer;
N-((5S)-3-[3-fluoro-4-(1-imino-1-oxidohexahydro-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanethioamide (Z)-isomer;
N-((5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer;
N-((5S)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;
N-((5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-{[(methylamino)carbonyl]imino}-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-[[ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-{{[(4-nitrophenyl)amino]carbonyl]imino}-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide,
Z-isomer ;

N-((5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-[(aminocarbonyl)methyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)cyclopropanecarbothioamide, *Z*-isomer;

N-[(5*S*)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]cyclopropanecarbothioamide, *Z*-isomer;

N-[(5*S*)-3-{3-fluoro-4-[1-[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, *Z*-isomer; or

N-((5*S*)-3-[3-fluoro-4-(1-{{[(benzylamino)carbonyl]imino}-1-oxidohexahydro-1*λ*⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl} methyl)acetamide, *Z*-isomer.

E'

Claim 66. (Currently Amended) A method for treating microbial infections comprising:
administering to a mammal in need thereof an effective amount of a compound of formula II as
shown in claim 47.
